The FDA approved the drug after two clinical trials demonstrated that it was both safe and effective. Participants in the trials received either the drug or the placebo every four weeks for a year.

Those who used the drug had fewer asthma attacks, including fewer attacks that led to emergency room visits and/or hospitalization.

Patients who start using Tezspire should not discontinue their inhaled or systemic corticosteroid asthma treatments abruptly. Any reductions should be gradual and under the direct supervision of a health care professional, the FDA said.

Those who have preexisting helminth infections (parasitic worm diseases) should be treated before starting Tezspire. People who start taking Tezspire should not have live vaccines, which include MMR, smallpox and rotavirus vaccines. The drug should also not be used to treat short-term asthma symptoms or attacks.

About 5% to 10% of Americans with asthma have severe asthma, which is an inflammatory disease that affects the lungs’ airways. Asthma causes the airways to become swollen or inflamed by certain triggers, including allergens or irritants and viral infections.

It can cause asthma attacks that make it hard to breathe and include wheezing, cough and chest tightness. Severe attacks can be intense and long-lasting. The symptoms of severe asthma typically do not get better with short-term treatments.

Source link